Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

References
1 Miravitlles M, Anzueto A. Chronic Respiratory Infection in Patients with Chronic Obstructive Pulmonary Disease: What Is the Role of Antibiotics? Int J Mol Sci. 2017;18(7) doi: 10.3390/ijms18071344
2 Evensen AE. Management of COPD exacerbations. Am Fam Physician. 2010;81(5):607-613.
3 Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;12:CD010257. doi: 10.1002/14651858.CD010257
4 Puhan MA, Vollenweider D, Latshang T, Steurer J, Steurer-Stey C. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir Res. 2007;8:30. doi: 10.1186/1465-9921-8-30
5 Wedzicha JA, Miravitlles M, Hurst JR et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. European Respiratory Journal. 2017;49:1600791. doi: 10.1183/13993003.00791-2016
6 Cole JM, Sheehan AH, Jordan JK. Concomitant use of ipratropium and tiotropium in chronic obstructive pulmonary disease. Ann Pharmacother. 2012;46(12):1717-1721. doi: 10.1345/aph.1R283
7 Leuppi JD, Schuetz P, Bingisser R et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309(21):2223-2231. doi: 10.1001/jama.2013.5023
8 Combined use of tiotropium (Spiriva) and ipratropium (Atrovent). Pharmacist's Letter/Prescriber's Letter. 2008;24(1):240109.
9 Albert RK, Connett J, Bailey WC et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689-698. doi: 10.1056/NEJMoa1104623
10 VA/DoD clinical practice guideline for management of outpatient chronic obstructive pulmonary disease. Washington, D.C.: Department of Veterans Affairs (VA); Department of Defense (DoD), 2007. Accessed September 15, 2017.
11 Wedzicha JA, Banerji D, Chapman KR et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374(23):2222-2234. doi: 10.1056/NEJMoa1516385
12 Yawn BP. Differential assessment and management of asthma vs chronic obstructive pulmonary disease. Medscape J Med. 2009;11(1):20.
13 Ferguson,G.T.; Make,B. (2017) Management of stable chronic obstructive pulmonary disease; [updated 2018 Jan 11]. UpToDate. Available from https://www.uptodate.com/
14 Bourdet SV, Williams DM. Chronic obstructive pulmonary disease. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach, 9th ed. New York: McGraw-Hill Education, 2014.
15 Dobler CC, Morrow AS, Beuschel B, et al. Pharmacologic Therapies in Patients with Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review with Meta-analysis. Ann Intern Med. 2020;172(6):413‐422. doi:10.7326/M19-3007

Pathway does not replace clinical judgment and should be modified as needed for individual patients. Page last revised 07/05/2017 .
Please send comments to: piercerp@health.missouri.edu

© Curators of the University of Missouri. All rights reserved. DMCA and other copyright information. An equal opportunity/affirmative action institution.
Published by the Department of Family & Community Medicine , Columbia, MO 65211